/C O R R E C T I O N -- Andelyn Biosciences/
RegulatoryapprovedFAYUVIPositive
AI Analysis
Summary
Ultragenyx's FAYUVI received FDA approval for treating Sanfilippo Syndrome Type A (MPS IIIA), marking a milestone for Andelyn Biosciences' Curator Platform in gene therapy manufacturing. This represents the first FDA-approved commercial gene therapy manufacturing milestone using the platform.
Outcome Details
FDA approval of Ultragenyx's FAYUVI for Sanfilippo Syndrome Type A (MPS IIIA)
Importance:8/10
Sentiment:
0.80
FDA approvalgene therapymanufacturingSanfilippo SyndromeMPS IIIArare disease
Related Companies
Read the original article
Published by PR Newswire Biotech on September 18, 2026 1:00 PM